Literature DB >> 20306059

Genomics approach to the analysis of bacterial communities dynamics in Hirschsprung's disease-associated enterocolitis: a pilot study.

C De Filippo1, A Pini-Prato, G Mattioli, S Avanzini, G Rapuzzi, D Cavalieri, M Di Paola, I Stefanini, I Ceccherini, D Mavilio, P Lionetti, V Jasonni.   

Abstract

INTRODUCTION: The most invalidating and life-threatening complication in Hirschsprung's disease patients (HSCR) is Hirschsprung's disease-associated enterocolitis (HAEC). The mechanisms underlying enterocolitis have not been identified. The limited knowledge of the role of intestinal microflora is in part due to the complexity of the intestinal microbiome and to the limitation of cultivation-based technologies, given that less than 25% of the intestinal bacterial species can be cultured.
MATERIALS AND METHODS: We used amplified ribosomal DNA restriction analysis (ARDRA) with four different restriction enzymes to study variations of microflora composition of the stools of a selected HSCR patient in different clinical conditions (acute phase vs. remission).
RESULTS: We assessed a total of 15 stool specimens belonging to the same 3-year-old male patient suffering from HSCR, which were harvested during 4 HAEC episodes and remission phases. Restriction analysis showed that HAEC episodes seem to cluster together at ARDRA analysis, thus suggesting a sort of predisposing bacterial community for HAEC development and the need for a microflora equilibrium to maintain wellness.
CONCLUSIONS: This approach proved to be effective, useful and powerful in assessing microflora dynamics and indicated that the differences in microflora associated with acute HAEC or remission are likely to result from a combination of disease activity and different antibiotic therapies. ARDRA proved to be useful in discriminating disease versus remission. Our findings indicated that HAEC results from a change in the equilibrium between bacterial species or from altered discrimination of harmless from harmful microorganisms, challenging the definition of pathogenic and non-pathogenic species. Based on these results, we propose ARDRA as a rapid inexpensive tool to assess microflora dynamics during HAEC episodes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306059     DOI: 10.1007/s00383-010-2586-5

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  28 in total

Review 1.  New insights into the pathogenesis of Hirschsprung's associated enterocolitis.

Authors:  Feilim Murphy; Prem Puri
Journal:  Pediatr Surg Int       Date:  2005-09-30       Impact factor: 1.827

2.  Isolation of DNA from bacterial samples of the human gastrointestinal tract.

Authors:  Erwin G Zoetendal; Hans G H J Heilig; Eline S Klaassens; Carien C G M Booijink; Michiel Kleerebezem; Hauke Smidt; Willem M de Vos
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells.

Authors:  Hiroshi Chinen; Katsuyoshi Matsuoka; Toshiro Sato; Nobuhiko Kamada; Susumu Okamoto; Tadakazu Hisamatsu; Taku Kobayashi; Hirotoshi Hasegawa; Akira Sugita; Fukunori Kinjo; Jiro Fujita; Toshifumi Hibi
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

4.  Hirschsprung's disease in Japan: analysis of 3852 patients based on a nationwide survey in 30 years.

Authors:  Sachiyo Suita; Tomoaki Taguchi; Satoshi Ieiri; Takanori Nakatsuji
Journal:  J Pediatr Surg       Date:  2005-01       Impact factor: 2.545

Review 5.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

6.  Metagenomic analysis of the human distal gut microbiome.

Authors:  Steven R Gill; Mihai Pop; Robert T Deboy; Paul B Eckburg; Peter J Turnbaugh; Buck S Samuel; Jeffrey I Gordon; David A Relman; Claire M Fraser-Liggett; Karen E Nelson
Journal:  Science       Date:  2006-06-02       Impact factor: 47.728

7.  Comparison of amplified ribosomal DNA restriction analysis, random amplified polymorphic DNA analysis, and amplified fragment length polymorphism fingerprinting for identification of Acinetobacter genomic species and typing of Acinetobacter baumannii.

Authors:  J G Koeleman; J Stoof; D J Biesmans; P H Savelkoul; C M Vandenbroucke-Grauls
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  Evaluation of the applicability of amplified rDNA-restriction analysis (ARDRA) to identification of species of the genus Corynebacterium.

Authors:  M Vaneechoutte; P Riegel; D de Briel; H Monteil; G Verschraegen; A De Rouck; G Claeys
Journal:  Res Microbiol       Date:  1995-10       Impact factor: 3.992

9.  Development of the human infant intestinal microbiota.

Authors:  Chana Palmer; Elisabeth M Bik; Daniel B DiGiulio; David A Relman; Patrick O Brown
Journal:  PLoS Biol       Date:  2007-06-26       Impact factor: 8.029

10.  Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derive from a single ancestral combination of alleles.

Authors:  F Lantieri; P Griseri; F Puppo; R Campus; G Martucciello; R Ravazzolo; M Devoto; I Ceccherini
Journal:  Ann Hum Genet       Date:  2006-01       Impact factor: 1.670

View more
  16 in total

Review 1.  Established and emerging concepts in Hirschsprung's-associated enterocolitis.

Authors:  Ankush Gosain
Journal:  Pediatr Surg Int       Date:  2016-01-19       Impact factor: 1.827

Review 2.  Recent developments in Hirschsprung's-associated enterocolitis.

Authors:  Elizabeth M Pontarelli; Henri R Ford; Christopher P Gayer
Journal:  Curr Gastroenterol Rep       Date:  2013-08

Review 3.  Hirschsprung's associated enterocolitis.

Authors:  Ankush Gosain; Adam S Brinkman
Journal:  Curr Opin Pediatr       Date:  2015-06       Impact factor: 2.856

4.  Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial.

Authors:  Xiaolin Wang; Zhi Li; Zhilin Xu; Zhongrong Wang; Jiexiong Feng
Journal:  Int J Colorectal Dis       Date:  2014-11-05       Impact factor: 2.571

Review 5.  Current understanding of Hirschsprung-associated enterocolitis: Pathogenesis, diagnosis and treatment.

Authors:  Ruth A Lewit; Korah P Kuruvilla; Ming Fu; Ankush Gosain
Journal:  Semin Pediatr Surg       Date:  2022-04-08       Impact factor: 1.900

6.  Different Fecal Microbiota in Hirschsprung's Patients With and Without Associated Enterocolitis.

Authors:  Alexis P Arnaud; Ianis Cousin; Françoise Schmitt; Thierry Petit; Benoit Parmentier; Guillaume Levard; Guillaume Podevin; Audrey Guinot; Stéphan DeNapoli; Erik Hervieux; Valérie Flaum; Philine De Vries; Gwénaëlle Randuineau; Sandrine David-Le Gall; Sylvie Buffet-Bataillon; Gaëlle Boudry
Journal:  Front Microbiol       Date:  2022-06-30       Impact factor: 6.064

7.  Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung's disease.

Authors:  Joseph F Pierre; Amanda J Barlow-Anacker; Christopher S Erickson; Aaron F Heneghan; Glen E Leverson; Scot E Dowd; Miles L Epstein; Kenneth A Kudsk; Ankush Gosain
Journal:  J Pediatr Surg       Date:  2014-08       Impact factor: 2.545

Review 8.  Hirschsprung-associated enterocolitis: prevention and therapy.

Authors:  Philip K Frykman; Scott S Short
Journal:  Semin Pediatr Surg       Date:  2012-11       Impact factor: 2.754

9.  Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung's Disease.

Authors:  Ankush Gosain; Amanda J Barlow-Anacker; Chris S Erickson; Joseph F Pierre; Aaron F Heneghan; Miles L Epstein; Kenneth A Kudsk
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

10.  Dynamic changes in microbiota and mycobiota during spontaneous 'Vino Santo Trentino' fermentation.

Authors:  Irene Stefanini; Davide Albanese; Agostino Cavazza; Elena Franciosi; Carlotta De Filippo; Claudio Donati; Duccio Cavalieri
Journal:  Microb Biotechnol       Date:  2016-01-18       Impact factor: 5.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.